, ,

Chris McCurdyChris McCurdy, Ph.D., R.Ph., is professor of medicinal chemistry and pharmacology at the University of Mississippi School of Pharmacy. He is currently serving as the chair of the 2013 Annual Meeting Program Committee and will begin a term of service as member-at-large on the AAPS Executive Council this autumn.

As chair of the Annual Meeting Program Committee, I am thrilled to report that it has been a busy year for pharmaceutical science! Presently, there are countless issues affecting pharmaceutical scientists, and the American Association of Pharmaceutical Scientists (AAPS) community is moving as quickly as ever in response.

At this year’s AAPS Annual Meeting and Exposition, experts from an array of fields will gather in San Antonio to deliberate and exchange their thoughts on the most cutting-edge science. With over 2,200 contributed papers, this meeting is sure to comprise all of the latest advances. We look forward to having several AAPS sections offer open forums during the meeting. These forums will cover a range of subjects including Immunogenicity Testing Strategies for Biological Therapeutics, Post-Approval Lifecycle Quality Management of Pharmaceuticals and Biopharmaceuticals, Converting Drug Product Manufacturing from Batch to Continuous, and many more.

In addition to the forums, the meeting will also present six short courses. With courses covering subjects from Quality Control of Nanoparticulate Drugs to Accelerating Global Product Registration, there is sure to be something for everyone. Also, four new hot topic sessions will highlight both small and large pharma, including New FDA Requirements for Establishing Bioequivalence of Drugs with Narrow Therapeutic Index, Regulatory Issues Related to Novel and Generic Peptide Drug, Extemporaneous Pharmaceutical Sterile Compounding, and Cardiovascular Safety in Early Drug Development.

And, finally, one major change to the meeting this year has been the addition of a programming slot for a late breaking topic, and this year’s is entitled Breakthrough Therapy: Are Innovators Enjoying Sweet Success or Is the Pathway Not Baked Yet? This session discusses how the rapid development of a drug requires both the sponsors and FDA to think outside the box, be more innovative, collaborate, and establish clear and transparent pathways for communication.

I hope everyone is looking forward to a meeting that will extend your professional and intellectual boundaries and widen your personal network with scientists from all fields related to pharmaceutical sciences.  For more detailed information on all of the exciting offerings at the 2013 AAPS Annual Meeting please read the October/November AAPS Newsmagazine.